Literature DB >> 20890633

Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents.

Wen-Tai Li1, Der-Ren Hwang, Jen-Shin Song, Ching-Ping Chen, Tung-Wei Chen, Chi-Hung Lin, Jiunn-Jye Chuu, Tzu-Wen Lien, Tsu-An Hsu, Chen-Lung Huang, Huan-Yi Tseng, Chu-Chung Lin, Heng-Liang Lin, Chung-Ming Chang, Yu-Sheng Chao, Chiung-Tong Chen.   

Abstract

Designed from a high throughput screened hit compound, novel 2-amino-1-thiazolyl imidazoles were synthesized and demonstrated cytotoxicity against human cancer cells. 1-(4-Phenylthiazol-2-yl)-4-(thiophen-2-yl)-1H-imidazol-2-amine (compound 2), a 2-amino-1-thiazolyl imidazole, inhibited tubulin polymerization, interacted with the colchicine-binding sites of tubulins, and caused cell cycle arrest at the G(2)/M phase in human gastric cancer cells. Disruption of the microtubule structure in cancer cells by compound 2 was also observed. Compound 2 concentration-dependently inhibited the proliferation of cancer cells in histocultured human gastric and colorectal tumors. Given orally, compound 2 prolonged the lifespans of leukemia mice intraperitoneally inoculated with the murine P388 leukemic cells. We report 2-amino-1-thiazolyl imidazoles as a novel class of orally active microtubule-destabilizing anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890633     DOI: 10.1007/s10637-010-9547-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  35 in total

Review 1.  Biotransformation reactions of five-membered aromatic heterocyclic rings.

Authors:  Deepak K Dalvie; Amit S Kalgutkar; S Cyrus Khojasteh-Bakht; R Scott Obach; John P O'Donnell
Journal:  Chem Res Toxicol       Date:  2002-03       Impact factor: 3.739

Review 2.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

3.  Novel combretastatin analogues endowed with antitumor activity.

Authors:  Daniele Simoni; Romeo Romagnoli; Riccardo Baruchello; Riccardo Rondanin; Michele Rizzi; Maria Giovanna Pavani; Domenico Alloatti; Giuseppe Giannini; Marcella Marcellini; Teresa Riccioni; Massimo Castorina; Mario B Guglielmi; Federica Bucci; Paolo Carminati; Claudio Pisano
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

Review 4.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.

Authors:  Edith A Perez
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

5.  MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.

Authors:  Shailaja Kasibhatla; Vijay Baichwal; Sui Xiong Cai; Bruce Roth; Ira Skvortsova; Sergej Skvortsov; Peter Lukas; Nicole M English; Nilantha Sirisoma; John Drewe; Azra Pervin; Ben Tseng; Robert O Carlson; Christopher M Pleiman
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

Review 6.  Animal models of chemotherapy-evoked painful peripheral neuropathies.

Authors:  Nicolas Authier; David Balayssac; Fabien Marchand; Bing Ling; Aude Zangarelli; Juliette Descoeur; François Coudore; Emmanuel Bourinet; Alain Eschalier
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 7.  Combretastatin a-4 analogs as anticancer agents.

Authors:  Anurag Chaudhary; S N Pandeya; P Kumar; P P Sharma; S Gupta; N Soni; K K Verma; G Bhardwaj
Journal:  Mini Rev Med Chem       Date:  2007-12       Impact factor: 3.862

8.  Effect of solution variables on the binding of vinblastine to tubulin.

Authors:  W D Singer; R T Hersh; R H Himes
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

Review 9.  Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

Authors:  A Jordan; J A Hadfield; N J Lawrence; A T McGown
Journal:  Med Res Rev       Date:  1998-07       Impact factor: 12.944

Review 10.  Docetaxel: an alternative taxane in ovarian cancer.

Authors:  N Katsumata
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

View more
  1 in total

Review 1.  Imidazoles as potential anticancer agents.

Authors:  Imran Ali; Mohammad Nadeem Lone; Haasan Y Aboul-Enein
Journal:  Medchemcomm       Date:  2017-04-13       Impact factor: 3.597

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.